JNJ-73763989 Market Size, Forecast, and Emerging Insight - 2032

"JNJ-73763989 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about JNJ-73763989 for chronic hepatitis B in the six major markets. A detailed picture of the JNJ-73763989 for chronic hepatitis B in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019 -2032 is provided in this report along with a detailed description of the JNJ-73763989 for chronic hepatitis B. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the JNJ-73763989 market forecast analysis for chronic hepatitis B in the 6MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic hepatitis B.

Drug Summary:

JNJ-3989, formerly ARO-HBV, a third-generation subcutaneously administered RNAi therapeutic candidate, was developed as a potential treatment for patients with chronic HBV infection in collaboration with Arrowhead Pharmaceuticals and Janssen Pharmaceuticals. ARO-HBV contains two siRNAs directly conjugated to N-acetyl galactosamine for hepatocyte delivery. ARO-HBV silences all mRNAs formed from covalently closed circular DNA (cccDNA) and host-integrated viral DNA. ARO-HBV is administered subcutaneously, so no absorption-related drug-drug interactions (DDI) occur.

JNJ-56136379 (JNJ-6379) is a Capsid Assembly Modulator (CAMs) being developed by Janssen Sciences. It works via a dual mechanism of action, formerly by interfering with capsid assembly and preventing covalently closed circular DNA (cccDNA) formation at de novo infection. It gets attached to the HBV core protein and obstructs both early and late-stage processes in the HBV life cycle. This drug in the monotherapy regimen is discontinued for further development due to the viral breakthrough observed in Phase II.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the JNJ-73763989 description, mechanism of action, dosage and administration, research and development activities in chronic hepatitis B.
• Elaborated details on JNJ-73763989 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the JNJ-73763989 research and development activities in chronic hepatitis B across the United States and Europe.
• The report also covers the patents information with expiry timeline around JNJ-73763989.
• The report contains forecasted sales of JNJ-73763989 for chronic hepatitis B till 2032.
• Comprehensive coverage of the late-stage emerging therapies for chronic hepatitis B.
• The report also features the SWOT analysis with analyst views for JNJ-73763989 in chronic hepatitis B.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

JNJ-73763989 Analytical Perspective by DelveInsight

• In-depth JNJ-73763989 Market Assessment

This report provides a detailed market assessment of JNJ-73763989 for chronic hepatitis B in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom. This segment of the report provides forecasted sales data from 2027 to 2032.

• JNJ-73763989 Clinical Assessment

The report provides the clinical trials information of JNJ-73763989 for chronic hepatitis B covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for chronic hepatitis B is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence JNJ-73763989 dominance.
• Other emerging products for chronic hepatitis B are expected to give tough market competition to JNJ-73763989 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of JNJ-73763989 in chronic hepatitis B.
• Our in-depth analysis of the forecasted sales data of JNJ-73763989 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the JNJ-73763989 in chronic hepatitis B.

Key Questions:

• What is the product type, route of administration and mechanism of action of JNJ-73763989?
• What is the clinical trial status of the study related to JNJ-73763989 in chronic hepatitis B and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the JNJ-73763989 development?
• What are the key designations that have been granted to JNJ-73763989 for chronic hepatitis B?
• What is the forecasted market scenario of JNJ-73763989 for chronic hepatitis B?
• What are the forecasted sales of JNJ-73763989 in the six major countries, including the United States, Europe (Germany, France, Italy, Spain), and the United Kingdom?
• What are the other emerging products available and how are these giving competition to JNJ-73763989 for chronic hepatitis B?
• Which are the late-stage emerging therapies under development for the treatment of chronic hepatitis B?